Palvella Therapeutics (PVLA) Stock Forecast & Price Target

Compare

694 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PVLA Analyst Ratings

Strong Buy

15 Buy

0 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Palvella

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PVLA Stock 12 Month Forecast

Average Price Target

$173.20

▲(88.45% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is $173.20 with a high forecast of $212.00 and a low forecast of $70.00. The average price target represents a 88.45% change from the last price of $91.91.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","112":"$112","213":"$213","61.5":"$61.5","162.5":"$162.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":212,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$212.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":173.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$173.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,61.5,112,162.5,213],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.53,103.56615384615385,112.60230769230769,121.63846153846154,130.67461538461538,139.71076923076924,148.74692307692308,157.78307692307692,166.81923076923078,175.85538461538462,184.89153846153846,193.92769230769233,202.96384615384616,{"y":212,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.53,100.58153846153846,106.63307692307693,112.68461538461538,118.73615384615384,124.78769230769231,130.83923076923077,136.89076923076922,142.94230769230768,148.99384615384616,155.0453846153846,161.09692307692308,167.14846153846153,{"y":173.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.53,92.64307692307692,90.75615384615385,88.86923076923077,86.9823076923077,85.09538461538462,83.20846153846153,81.32153846153847,79.43461538461538,77.5476923076923,75.66076923076923,73.77384615384615,71.88692307692308,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$212.00

Average Price Target$173.20

Lowest Price Target$70.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Whitney Ijem

Canaccord Genuity

$148→$204

Buy

121.96%

Upside

Reiterated

12/16/25

Palvella Therapeutics (PVLA) Gets a Buy from Canaccord Genuity

Danielle Brill

Truist Financial

$105→$190

Buy

106.72%

Upside

Reiterated

12/16/25

Palvella Therapeutics price target raised to $190 from $105 at TruistPalvella Therapeutics price target raised to $190 from $105 at Truist

Albert Lowe

Craig-Hallum

$175

Buy

90.40%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Champions Oncology (NASDAQ: CSBR) and NeoGenomics (NASDAQ: NEO)

Andrew Fein

H.C. Wainwright

$190→$200

Buy

117.60%

Upside

Reiterated

12/15/25

Promising Clinical Data and Market Potential Drive Buy Rating for Palvella Therapeutics' QTORIN Rapamycin

Ritu Baral

TD Cowen

$97→$133

Buy

44.71%

Upside

Reiterated

12/15/25

Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst

Sam Slutsky

LifeSci Capital

$130→$150

Buy

63.20%

Upside

Reiterated

12/15/25

Buy Rating Affirmed for Palvella Therapeutics Following Promising Phase 2 TOIVA Trial Results

Joshua Schimmer

Cantor Fitzgerald

$200→$210

Buy

128.48%

Upside

Reiterated

12/15/25

Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald

Geulah Livshits

Chardan Capital

$110→$174

Buy

89.32%

Upside

Reiterated

12/15/25

Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), Palvella Therapeutics (PVLA)

Trevor Allred

Oppenheimer

$120→$200

Buy

117.60%

Upside

Reiterated

12/15/25

Palvella Therapeutics price target raised to $200 from $120 at OppenheimerPalvella Therapeutics price target raised to $200 from $120 at Oppenheimer

Jeet Mukherjee

BTIG

$167→$192

Buy

108.90%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Palvella Therapeutics (NASDAQ: PVLA)

Dev Prasad

Lucid Capital

$122→$212

Buy

130.66%

Upside

Reiterated

12/15/25

Palvella Therapeutics price target raised to $212 from $122 at Lucid CapitalPalvella Therapeutics price target raised to $212 from $122 at Lucid Capital

Kaveri Pohlman

Clear Street

$200

Buy

117.60%

Upside

Initiated

12/05/25

Palvella Therapeutics initiated with a Buy at Clear StreetPalvella Therapeutics initiated with a Buy at Clear Street

Annabel Samimy

Stifel Nicolaus

$87→$145

Buy

57.76%

Upside

Reiterated

11/24/25

Stifel Nicolaus Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Ryan Deschner

Raymond James

$92→$143

Buy

55.59%

Upside

Upgraded

11/19/25

Palvella Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesPalvella Therapeutics upgraded to Strong Buy from Outperform at Raymond James

Catherine Novack

JonesTrading

$56→$70

Buy

-23.84%

Downside

Reiterated

09/25/25

JonesTrading Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Whitney Ijem

Canaccord Genuity

$148→$204

Buy

121.96%

Upside

Reiterated

12/16/25

Palvella Therapeutics (PVLA) Gets a Buy from Canaccord Genuity

Danielle Brill

Truist Financial

$105→$190

Buy

106.72%

Upside

Reiterated

12/16/25

Palvella Therapeutics price target raised to $190 from $105 at TruistPalvella Therapeutics price target raised to $190 from $105 at Truist

Albert Lowe

Craig-Hallum

$175

Buy

90.40%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Champions Oncology (NASDAQ: CSBR) and NeoGenomics (NASDAQ: NEO)

Andrew Fein

H.C. Wainwright

$190→$200

Buy

117.60%

Upside

Reiterated

12/15/25

Promising Clinical Data and Market Potential Drive Buy Rating for Palvella Therapeutics' QTORIN Rapamycin

Ritu Baral

TD Cowen

$97→$133

Buy

44.71%

Upside

Reiterated

12/15/25

Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst

Sam Slutsky

LifeSci Capital

$130→$150

Buy

63.20%

Upside

Reiterated

12/15/25

Buy Rating Affirmed for Palvella Therapeutics Following Promising Phase 2 TOIVA Trial Results

Joshua Schimmer

Cantor Fitzgerald

$200→$210

Buy

128.48%

Upside

Reiterated

12/15/25

Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald

Geulah Livshits

Chardan Capital

$110→$174

Buy

89.32%

Upside

Reiterated

12/15/25

Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), Palvella Therapeutics (PVLA)

Trevor Allred

Oppenheimer

$120→$200

Buy

117.60%

Upside

Reiterated

12/15/25

Palvella Therapeutics price target raised to $200 from $120 at OppenheimerPalvella Therapeutics price target raised to $200 from $120 at Oppenheimer

Jeet Mukherjee

BTIG

$167→$192

Buy

108.90%

Upside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Palvella Therapeutics (NASDAQ: PVLA)

Dev Prasad

Lucid Capital

$122→$212

Buy

130.66%

Upside

Reiterated

12/15/25

Palvella Therapeutics price target raised to $212 from $122 at Lucid CapitalPalvella Therapeutics price target raised to $212 from $122 at Lucid Capital

Kaveri Pohlman

Clear Street

$200

Buy

117.60%

Upside

Initiated

12/05/25

Palvella Therapeutics initiated with a Buy at Clear StreetPalvella Therapeutics initiated with a Buy at Clear Street

Annabel Samimy

Stifel Nicolaus

$87→$145

Buy

57.76%

Upside

Reiterated

11/24/25

Stifel Nicolaus Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Ryan Deschner

Raymond James

$92→$143

Buy

55.59%

Upside

Upgraded

11/19/25

Palvella Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesPalvella Therapeutics upgraded to Strong Buy from Outperform at Raymond James

Catherine Novack

JonesTrading

$56→$70

Buy

-23.84%

Downside

Reiterated

09/25/25

JonesTrading Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Palvella Therapeutics

1 Month

xxx

Success Rate

5/5 ratings generated profit

Average Return

+25.00%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +25.00% per trade.

3 Months

xxx

Success Rate

6/6 ratings generated profit

Average Return

+49.75%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +49.75% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

10/10 ratings generated profit

Average Return

+284.50%

reiterated a buy rating 5 days ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +284.50% per trade.

2 Years

xxx

Success Rate

10/10 ratings generated profit

Average Return

+284.50%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +284.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PVLA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PVLA has received 37 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PVLA average Analyst price target in the past 3 months is 173.20.

Each month's total comprises the sum of three months' worth of ratings.

PVLA Financial Forecast

PVLA Earnings Forecast

Next quarter’s earnings estimate for PVLA is -$0.91 with a range of -$1.06 to -$0.31. The previous quarter’s EPS was -$1.03. PVLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Sales Forecast

Next quarter’s sales forecast for PVLA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PVLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Stock Forecast FAQ

What is PVLA’s average 12-month price target, according to analysts?

Based on analyst ratings, Palvella Therapeutics’s 12-month average price target is 173.20.

What is PVLA’s upside potential, based on the analysts’ average price target?

Palvella Therapeutics has 88.45% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PVLA a Buy, Sell or Hold?

Palvella Therapeutics has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.

What is Palvella Therapeutics’s price target?

The average price target for Palvella Therapeutics is 173.20. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $212.00 ,the lowest forecast is $70.00. The average price target represents 88.45% Increase from the current price of $91.91.

What do analysts say about Palvella Therapeutics?

Palvella Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of PVLA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Palvella Therapeutics (PVLA) Stock Forecast & Price Target

PVLA Analyst Ratings

PVLA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Palvella Therapeutics

PVLA Analyst Recommendation Trends

PVLA Financial Forecast

PVLA Earnings Forecast

PVLA Sales Forecast

PVLA Stock Forecast FAQ

Detailed List of Analyst Forecasts